Valbiotis SAS Total Liabilities

Latest as of December 2025: €7.43 Million EUR ≈ $8.68 Million USD

Valbiotis SAS total liabilities. Based on the latest financial reports, Valbiotis SAS (ALVAL) has total liabilities worth €7.43 Million EUR (≈ $8.68 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Valbiotis SAS to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Valbiotis SAS (2015–2025)

Total liabilities of Valbiotis SAS from 2015 to 2025. This chart illustrates how Valbiotis SAS's total liabilities have evolved over time, based on quarterly financial data. Explore Valbiotis SAS long-term investment allocation to see how much of total assets are deployed in long-term investments.

Valbiotis SAS Competitors by Total Liabilities

The table below lists competitors of Valbiotis SAS ranked by their total liabilities.

Company Country Total Liabilities
Ledtech Electronics Corp
TW:6164
Taiwan NT$515.19 Million
Wir Asia Tbk PT
JK:WIRG
Indonesia Rp642.11 Billion
Derwent London PLC
LSE:DLN
UK GBX1.70 Billion
Cue Biopharma
NASDAQ:CUE
USA $18.40 Million
Medicenna Therapeutics Corp
TO:MDNA
Canada CA$6.85 Million
INSPIREMD 1/18 DL-0001
F:II2
Germany €14.20 Million
Inmobiliaria Park Rose Iberoamericana SOCIMI SA
MC:YPARK
Spain €11.04 Million
Tulikivi Oyj A
HE:TULAV
Finland €19.10 Million

Liability Composition Analysis (2015–2025)

This chart breaks down Valbiotis SAS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ALVAL current and non-current assets.

Liquidity & Leverage Metrics

Valbiotis SAS Total Liabilities Ratios Explained

Valbiotis SAS total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 2.85 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio 1.57 Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.07 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.52 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Valbiotis SAS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Valbiotis SAS (2015–2025)

The table below shows the annual total liabilities of Valbiotis SAS from 2015 to 2025.

Year Total Liabilities Change
2025-12-31 €7.43 Million
≈ $8.68 Million
-19.60%
2024-12-31 €9.24 Million
≈ $10.80 Million
-32.62%
2023-12-31 €13.71 Million
≈ $16.03 Million
-1.08%
2022-12-31 €13.86 Million
≈ $16.20 Million
-2.72%
2021-12-31 €14.25 Million
≈ $16.66 Million
+2.29%
2020-12-31 €13.93 Million
≈ $16.28 Million
+104.63%
2019-12-31 €6.81 Million
≈ $7.96 Million
+51.35%
2018-12-31 €4.50 Million
≈ $5.26 Million
+76.15%
2017-12-31 €2.55 Million
≈ $2.98 Million
+103.43%
2016-12-31 €1.25 Million
≈ $1.47 Million
+16.31%
2015-12-31 €1.08 Million
≈ $1.26 Million
--

About Valbiotis SAS

PA:ALVAL France Packaged Foods
Market Cap
$26.56 Million
€22.71 Million EUR
Market Cap Rank
#23955 Global
#382 in France
Share Price
€0.64
Change (1 day)
+0.00%
52-Week Range
€0.50 - €1.21
All Time High
€10.54
About

Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia. The company offers supplements for immunity and vitality, health and wellbeing, metabolic and cardiovascular health, and beauty and physical comfort. It also develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; T… Read more